Skip to main content

Table 2 Univariate and multivariate Cox regression analyses for overall survival

From: Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era

  Univariate HR (95% CI) P Multivariate HR (95% CI) P
Patient-related factor
 Age (per 1 year) 1.01 (1.00–1.02) 0.005 1.02 (1.01–1.03) 0.003
 Sex (Male vs. Female) 1.02 (0.80–1.30) 0.889   
 KPS
  (80 vs. ≤70) 1.06 (0.79–1.42) 0.697   
  (≥90 vs. ≤70) 0.78 (0.58–1.06) 0.112   
 Baseline TLC (< 1000/μL vs. ≥1000/μL) 1.25 (0.94–1.64) 0.119   
Tumor-related factor
 Extent of resection
  (Subtotal/Partial vs. Total) 1.78 (1.38–2.31) <.001 1.75 (1.33–2.31) <.001
 (Biopsy vs. Total) 1.69 (1.06–2.70) 0.028 1.50 (0.93–2.43) 0.095
IDH1 mutation
  (Yes vs. No) 0.25 (0.11–0.55) <.001 0.30 (0.13–0.69) 0.005
  (Unknown vs. No) 1.14 (0.86–1.52) 0.360 0.97 (0.71–1.31) 0.818
 MGMT (Methylated vs. Unmethylated) 0.46 (0.35–0.60) <.001 0.48 (0.37–0.63) <.001
 Subventriclular zone (Involved vs. Uninvolved) 1.57 (1.23–2.01) <.001 1.52 (1.17–1.96) 0.001
Treatment-related factor
 The cumulative dose of temozolomide (per 100 mg/m2) 1.00 (0.99–1.00) 0.260 1.00 (0.99–1.01) 0.597
 PTV1 volume (per 10 cm3) 1.01 (1.00–1.01) 0.132   
 PTV2 volume (per 10 cm3) 1.02 (1.00–1.03) 0.029 1.01 (0.99–1.02) 0.305
 Radiotherapy modality (IMRT vs. 3D-CRT) 0.91 (0.71–1.17) 0.483   
 Total dose (per 1 Gy) 0.98 (0.95–1.01) 0.187   
 No. of fractionation (per 1) 0.99 (0.94–1.05) 0.845   
 Acute severe lymphopenia (Yes vs. No) 1.32 (1.03–1.69) 0.028 1.04 (0.81–1.35) 0.756
  1. Abbreviations: 3D-CRT three-dimensional conformal radiotherapy, CI confidence interval, HR hazard ratio, IMRT intensity-modulated radiotherapy, KPS Karnofsky performance status, PTV planning target volume, TLC total lymphocyte count